21-22 February, 2017

Molly Burich

Associate Director, Public Policy- Biosimilars, Pipeline, Reimbursement
Boehringer Ingelheim
Molly Burich, MS, is the Associate Director for Public Policy – Biosimilars, Pipeline and Reimbursement at Boehringer Ingelheim, Inc. In her role she focuses on key federal and state policy issues impacting the franchises of Boehringer Ingelheim, with specific focus on biosimilars, pipeline products and reimbursement for in-line and pipeline products.  Before joining Boehringer Ingelheim, Ms. Burich was an Associate Director of Mental Health Policy and Advocacy at Otsuka Product Development and Commercialization, Inc. In that role she focused on key mental health advocacy and policy issues at the state level. Prior to this role, Ms. Burich was a Senior Manager, Federal Government Affairs – Reimbursement and Policy at Otsuka. In that role, she focused on reimbursement and policy strategies to ensure patient access to products. Additionally, Ms. Burich focused on the implementation of healthcare reform and health policy strategies as they relate specifically to patient access and reimbursement. Prior to this role, Ms. Burich focused on strategic and operational considerations associated with reimbursement, patient access and patient hub programs within Otsuka.  Ms. Burich was also an Assistant Director for Xcenda, an AmerisourceBergen Consulting Services company based in North Carolina. At Xcenda, Ms. Burich focused on reimbursement and health policy issues as they related to strategic reimbursement planning.  Ms. Burich worked in collaboration with reimbursement, brand and managed markets teams across a variety of pharmaceutical and biotechnology clients across numerous disease states including, multiple sclerosis, hemophilia, oncology, mental health and rheumatoid arthritis.  Prior to joining Xcenda, Ms. Burich worked for Avalere Health, a health care policy consulting firm based in Washington, DC. In that role, Ms. Burich specialized in reimbursement strategy and product commercialization for new pharmaceuticals and biotechnologies. In addition, she closely monitored ongoing legislative and regulatory changes for pharmaceutical, biotechnology, and medical device companies.  Ms. Burich received a master of science in public service management with an emphasis in public policy from DePaul University and a bachelor of arts in political science from the University of Northern Colorado



Check out the incredible speaker line-up to see who will be joining Molly.

Download The Latest Agenda